Opendata, web and dolomites

Medicortex

Launching the First Non-Invasive Point of Care Diagnostic Test for Traumatic Brain Injury

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Medicortex project word cloud

Explore the words cloud of the Medicortex project. It provides you a very rough idea of what is the project "Medicortex" about.

evaluations    tests       record    25x    billion    ed    margin    aring    innovative    kit    spinal    market    depression    providers    accurate    identification    patient    correctly    medicortex    academia    impairment    lasse    charge    samples    standard    tools    industry    saliva    charged    medical    accurately    reduce    proven    sell    pharmaceutical    biotech    letter    single    putting    harel    limaa    dizziness    bioanalytical    founder    mild    auml    central    difficult    none    diagnostic    traumatic    exceed    anxiety    90    brain    healthcare    kvist    ct    director    injuries    rten    headache    biomarkers    instead    dr    irritability    25    unfortunately    500    cord    correlated    point    always    care    protected    scan    diagnostics    sufficient    distributors    patents    diagnose    risks    track    untreated    approved    moderate    urine    nervous    annually    quick    injury    head    biomarker    mri    poc    efficient    scans    suggested    cognitive    envision    glycan    innovation    50    price    confirmed    tbi    active   

Project "Medicortex" data sheet

The following table provides information about the project.

Coordinator
MEDICORTEX FINLAND OY 

Organization address
address: ITAINEN PITKAKATU 4B 4
city: TURKU
postcode: 20520
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.medicortex.fi
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDICORTEX FINLAND OY FI (TURKU) coordinator 50˙000.00

Map

 Project objective

Traumatic Brain Injury (TBI) is the leading cause of central nervous system impairment, over traumatic spinal cord injury. Mild and moderate TBI cases represent more than 90% of TBI injuries but are unfortunately the most difficult to accurately diagnose. Currently, standard TBI diagnostic tools are based on CT scans, MRI scans or cognitive evaluations which are not always sufficient accurate to correctly diagnose mild and moderate cases, putting the patient at risks (long-term consequences of untreated TBI include headache, dizziness, irritability, anxiety and depression). Medicortex is an innovative point of care test based on novel glycan-based biomarkers. The Medicortex diagnostic kit is a cost-efficient, quick and reliable test based on specific biomarkers for the identification of TBI in both saliva and urine samples. We have protected the innovation with several patents. Many biomarkers have been suggested for TBI but none has resulted in an approved test. We have already proven that our biomarker is strongly correlated with TBI, allowing us to address a TBI point of care (POC) diagnostics market that will exceed €2 billion annually. We will sell the Medicortex TBI tests and envision a price to distributors of €25. We expect distributors to charge €50 to healthcare providers and make a margin of 50%. This will reduce the TBI diagnostics cost by a factor of 10-25x for healthcare systems as a single test can be charged to the patient for less than €100 instead of €1,000 for a CT scan or €2,500 for an MRI scan. Two distributors have confirmed they interest in a letter. Our Founder Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Our Medical Director Dr. Mårten Kvist is active in academia and our Head of R&D Dr. Lasse Välimaa has a track record in R&D of bioanalytical methods and medical diagnostics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDICORTEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDICORTEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More